Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509555-13-00

Acronym

TG1101-RMS-SC101

Enrollment

164

Registered

2024-05-06

Start date

2024-05-15

Completion date

Unknown

Last updated

2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis, Relapsing multiple sclerosis

Brief summary

Pharmacokinetic assessment of intravenous and subcutaneous administration of ublituximab, B-cell count following intravenous and subcutaneous administration of ublituximab

Interventions

DRUGublituximab

DRUGPARACETAMOL

DRUGCETIRIZINE

DRUGUblituximab

DRUGMETHYLPREDNISOLONE

DRUGDEXAMETHASONE

DRUGDIPHENHYDRAMINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic assessment of intravenous and subcutaneous administration of ublituximab, B-cell count following intravenous and subcutaneous administration of ublituximab	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026